Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(40%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Terminated(4)
Other(1)

Detailed Status

Withdrawn2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

withdrawn240%
terminated240%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

NCT03699475
terminatedphase_1

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

NCT03733249
unknown

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

NCT03639844
withdrawnphase_1

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

NCT02786485
withdrawnphase_1

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

NCT03807063

Clinical Trials (5)

Showing 5 of 5 trials
NCT03699475Phase 2

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

Terminated
NCT03733249Phase 1

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Terminated
NCT03639844

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

Unknown
NCT02786485Phase 1

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Withdrawn
NCT03807063Phase 1

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5